Govt to set minimum penicillin import price, big boost for Aurobindo Pharma?Govt to set minimum penicillin import price, big boost for Aurobindo Pharma?

Introduction

Govt to approve Minimum Import Price for Penicillin-G to support local producers, ensuring domestic antibiotic production remains viable and sustaining investments under India’s Production-Linked Incentive scheme.

Also Read: Ceigall India shares soar 6% after bagging ₹1,089 Cr highway project

Share price movement of Aurobindo Pharma

On December 30, 2025, Aurobindo Pharma Ltd opened at ₹1,190.00, down 0.75% from its previous close of ₹1,199.00. The stock reached a high of ₹1,207.30 (0.69%) and a low of ₹1,180.95 (-1.50%). By 11:27 AM, it traded at ₹1,185.20, a 1.15% decrease, with a market cap of ₹68,836.61 crore.

Govt Sets Minimum Penicillin Import Price

The government is in the final stages of approving a Minimum Import Price (MIP) for Penicillin-G (Pen-G), a key raw material for antibiotics, to support domestic manufacturers.

The MIP can help domestic Pen-G producers survive price undercutting by Chinese suppliers and make Aurobindo Pharma’s investment under the PLI scheme commercially viable.

Hyderabad-based Aurobindo Pharma, one of India’s largest antibiotic makers, has invested over Rs 2,500 crore in Pen-G/6-APA facilities to enhance local self-sufficiency in fermentation-based APIs.

International Pen-G prices have dropped to around $13.5 per kg, below the domestic production cost of over $25 per kg, making local production unprofitable without government support.

The proposed MIP will be time-bound, typically one year, applying only to imports for domestic consumption, while export-linked imports will remain unaffected, preventing trade barriers.

Pen-G is critical for manufacturing antibiotics such as Amoxicillin and Ampicillin, essential to India’s healthcare system, and the MIP aims to strengthen local production under the PLI scheme.

Stock performance of Aurobindo Pharma for Period of 1 week, 6 months, and 1 year

Aurobindo Pharma Ltd delivered a -1.47% return over the past week, gained 3.81% over the past six months, and declined 7.56% over the past one year.

Also Read: Coforge to acquire Encora US in a $2.35 Bn deal to boost AI portfolio

Shareholding pattern of Aurobindo Pharma

Particulars	Sep 2025	Jun 2025	Mar 2025
Promoter	52%	52%	52%
FII	14.20%	14.40%	15.30%
DII	27.60%	26.90%	26.20%
Public	6.40%	6.90%	6.60%

About Aurobindo Pharma

Aurobindo Pharma Ltd (NSE: AUROPHARMA) is engaged in manufacturing and marketing active pharmaceutical ingredients, generic pharmaceuticals, and related services, serving domestic and international markets with a diverse portfolio of medicines and healthcare solutions.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs